Casey Kopczynski - Aerie Pharmaceuticals Co-Founder and Chief Scientific Officer
| AERIDelisted Stock | USD 15.25 0.01 0.07% |
Founder
Dr. Casey C. Kopczynski, Ph.D., is Chief Scientific Officer and CoFounder at Aerie Pharmaceuticals, Inc. he has served as our Chief Scientific Officer since cofounding our company in 2005. From 2002 to 2005, he was the Managing Partner at Biotech Initiative, LLC, a consulting practice dedicated to emerging biotech companies. He was also previously the Vice President of Research at Ercole Biotech, Inc. from 2003 to 2004, a company developing drugs for the treatment of cancer, inflammation and orphan genetic diseases. Prior to Ercole Biotech, Inc., Dr. Kopczynski was Director of Research and a founding member of the scientific staff at Exelixis, Inc. from 1996 to 2002 since 2005.
| Age | 61 |
| Tenure | 19 years |
| Professional Marks | Ph.D |
| Phone | 919 237-5300 |
| Web | www.aeriepharma.com |
Aerie Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0459) % which means that it has lost $0.0459 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (22.5501) %, meaning that it created substantial loss on money invested by shareholders. Aerie Pharmaceuticals' management efficiency ratios could be used to measure how well Aerie Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Aerie Pharmaceuticals currently holds 234.53 M in liabilities with Debt to Equity (D/E) ratio of 9.41, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Aerie Pharmaceuticals has a current ratio of 2.55, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Aerie Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina. Aerie Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 376 people. Aerie Pharmaceuticals (AERI) is traded on NASDAQ Exchange in USA and employs 376 people. Management Performance
| Return On Equity | -22.55 | |||
| Return On Asset | -0.0459 |
Aerie Pharmaceuticals Leadership Team
Elected by the shareholders, the Aerie Pharmaceuticals' board of directors comprises two types of representatives: Aerie Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aerie. The board's role is to monitor Aerie Pharmaceuticals' management team and ensure that shareholders' interests are well served. Aerie Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aerie Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wanda Francies, Head HR | ||
| Peter Lang, Chief Officer | ||
| Marvin Garrett, Head Assurance | ||
| Raj Kannan, Principal CEO | ||
| Jeffrey CPA, VP Officer | ||
| Carolyn McAuliffe, Director Communications | ||
| Casey Kopczynski, Co-Founder and Chief Scientific Officer | ||
| Michelle Senchyna, Head Operations | ||
| Craig Skenes, Head Devel | ||
| John Esq, G Sec |
Aerie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aerie Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -22.55 | |||
| Return On Asset | -0.0459 | |||
| Profit Margin | (0.17) % | |||
| Operating Margin | (0.12) % | |||
| Current Valuation | 918.14 M | |||
| Shares Outstanding | 49.42 M | |||
| Shares Owned By Insiders | 1.79 % | |||
| Shares Owned By Institutions | 98.21 % | |||
| Number Of Shares Shorted | 1.52 M | |||
| Price To Earning | (19.00) X |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Aerie Stock
If you are still planning to invest in Aerie Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aerie Pharmaceuticals' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |